APA (7th ed.) Citation

Magnolo, N., Soung, J., Frew, J., Costanzo, A., Ruiz-Santiago, H., Eyerich, K., . . . Warren, R. B. (2026). Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial. Dermatology & Therapy, 16(7), 3415. https://doi.org/10.1007/s13555-026-01779-x

Chicago Style (17th ed.) Citation

Magnolo, Nina, et al. "Risankizumab Versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial." Dermatology & Therapy 16, no. 7 (2026): 3415. https://doi.org/10.1007/s13555-026-01779-x.

MLA (9th ed.) Citation

Magnolo, Nina, et al. "Risankizumab Versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial." Dermatology & Therapy, vol. 16, no. 7, 2026, p. 3415, https://doi.org/10.1007/s13555-026-01779-x.